Jefferies Financial Group Begins Coverage on Yarrow Bioscience (NASDAQ:YARW)

Yarrow Bioscience logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Jefferies Financial Group initiated coverage with a “strong buy” rating. Overall, analyst sentiment is “Moderate Buy,” with an average price target of $52.67.
  • Yarrow shares were reported down 22.7%, opening at $13.93; the stock’s 52-week range is $12.39 to $46.95.
  • The company reported a quarterly loss of $0.43 per share, while institutional investors own 83.78% of its stock.
  • Five stocks to consider instead of Yarrow Bioscience.

Investment analysts at Jefferies Financial Group began coverage on shares of Yarrow Bioscience (NASDAQ:YARW - Get Free Report) in a note issued to investors on Sunday, Zacks reports. The brokerage set a "strong-buy" rating on the stock.

Several other research analysts have also recently weighed in on the stock. BTIG Research began coverage on shares of Yarrow Bioscience in a report on Monday, August 3rd. They set a "buy" rating and a $58.00 price objective for the company. Guggenheim started coverage on shares of Yarrow Bioscience in a report on Friday, November 6th. They issued a "buy" rating and a $60.00 target price on the stock. TD Cowen assumed coverage on shares of Yarrow Bioscience in a research report on Tuesday, July 28th. They issued a "buy" rating for the company. Finally, Wall Street Zen upgraded shares of Yarrow Bioscience to a "hold" rating in a research note on Saturday, August 22nd. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $52.67.

Get Our Latest Analysis on Yarrow Bioscience

Yarrow Bioscience Stock Down 22.7%

Shares of NASDAQ YARW opened at $13.93 on Friday. The firm's 50 day simple moving average is $21.55. Yarrow Bioscience has a fifty-two week low of $12.39 and a fifty-two week high of $46.95.

Yarrow Bioscience (NASDAQ:YARW - Get Free Report) last released its earnings results on Thursday, November 12th. The company reported ($0.43) EPS for the quarter. Yarrow Bioscience had a negative return on equity of 99.84% and a negative net margin of 4,726.21%.

Institutional Trading of Yarrow Bioscience

A number of large investors have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new stake in Yarrow Bioscience during the second quarter valued at approximately $1,301,400,000. Bellevue Group AG bought a new stake in shares of Yarrow Bioscience in the 3rd quarter valued at approximately $22,520,000. Soleus Capital Management L.P. purchased a new position in shares of Yarrow Bioscience in the 3rd quarter worth approximately $9,391,000. ADAR1 Capital Management LLC purchased a new position in shares of Yarrow Bioscience in the 2nd quarter worth approximately $1,920,000. Finally, Braidwell LP bought a new position in shares of Yarrow Bioscience during the 2nd quarter valued at approximately $596,000. Institutional investors own 83.78% of the company's stock.

Yarrow Bioscience Company Profile

(Get Free Report)

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.

Recommended Stories

Analyst Recommendations for Yarrow Bioscience (NASDAQ:YARW)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Yarrow Bioscience Right Now?

Before you consider Yarrow Bioscience, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Yarrow Bioscience wasn't on the list.

While Yarrow Bioscience currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines